januar 4, 2017
“We are very pleased with the strong interest in this financing round from leading life science and strategic corporate investors,” said Pieter Muntendam, MD, founder, president and CEO of scPharmaceuticals. “The additional funds will support our preparation for the commercial introduction of Furoscix and the sc2Wear Infusor, as well as further development of our antibiotic pipeline...
“As we near completion of enrollment in our pivotal Phase 2b/3 clinical trial of our lead drug candidate, VTS-270, our primary goal is to advance regulatory submissions. Assuming we receive favorable responses from U.S. and European regulatory agencies, our next goal will be to rapidly provide access to VTS-270 for the children suffering from NPC...


Hjernestimulation skal lindre symptomer ved Parkinsons sygdom
25. januar 2021
Minihjerner skal kaste lys over nervesygdomme
25. januar 2021
Mekanismer bag skizofreni
25. januar 2021


Lundbeckfonden Ventures

Lundbeckfonden Emerge